Related Experiment Video
Updated: Jun 6, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Similar observed CABG related bleeding complications in patients with and without clopidogrel loading doses
Shradha Rathi1, Pedro Lozano, Lindsay M Boeckman
1Department of Medicine, University of klahoma Health Sciences Center, Oklahoma City.
Insights
Clopidogrel pretreatment before coronary artery bypass graft (CABG) surgery did not increase bleeding complications. Patients on clopidogrel had a shorter hospital stay after CABG, suggesting its safety in this context.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Pharmacology
Background:
- Clopidogrel pretreatment improves outcomes after percutaneous coronary intervention.
- Patients undergoing elective coronary artery bypass graft (CABG) surgery may have received clopidogrel, raising concerns about increased bleeding risks.
- Assessing hemorrhagic complications and hospital stay in these patients is crucial.
Purpose of the Study:
- To evaluate hemorrhagic complications in stable patients undergoing elective CABG after clopidogrel pretreatment.
- To compare the length of hospital stay between patients who received clopidogrel and those who did not before CABG.
Main Methods:
- A retrospective study of 54 patients undergoing elective CABG.
- Patients were stratified into two groups: clopidogrel loading dose (n=20) and no clopidogrel (n=34).
- Comparison of major bleeding events (TIMI Bleeding index) and median post-surgical hospital stay.
Main Results:
- No significant difference in TIMI Bleeding index between groups (p=0.5).
- Incidence of major bleeding, significant hemoglobin loss, and blood transfusion requirements were similar.
- The no-clopidogrel group had a longer post-surgical hospital stay (median 7 days) compared to the clopidogrel group (median 5 days; p=0.006).
Conclusions:
- Clopidogrel pretreatment before CABG is not associated with increased bleeding complications or transfusion needs.
- Stable patients pretreated with clopidogrel can safely undergo CABG, with no significant increase in hemorrhagic risk if surgery is delayed by at least 7 days.
- The study suggests clopidogrel pretreatment may be associated with a shorter hospital stay post-CABG.
Objective:
Pretreatment with clopidogrel before percutaneous coronary intervention improves cardiovascular outcomes. However, some patients require elective coronary artery bypass graft (CABG) surgery instead, possibly increasing bleeding complications. We sought to assess the hemorrhagic complications and the length of hospital stay of stable patients receiving clopidogrel pretreatment that are referred for CABG.
Methods:
Between March and August 2007, 493 patients underwent diagnostic catheterization; 54 patients underwent elective CABG and were stratified according to clopidogrel loading dose (n = 20) or not (n = 34). Incidences of major hemorrhagic events and median post-surgical hospital stay were compared between groups.
Results:
TIMI Bleeding index was not significantly difference between the clopidogrel and not clopidogrel groups (mean difference 0.46; 95% CI -0.89 to 1.82; p = 0.5). The incidence of major TIMI bleeding (70% vs. 73.5%; p > 0.9), peak hemoglobin loss > 5 g/dL (60% vs. 38.2%; p = 0.2), and blood transfusion > 4 units (20% vs. 26.5%; p = 0.7) in clopidogrel vs. no-clopidogrel group were not statistically different. Interestingly, the post-surgical length of stay was longer for the no-clopidogrel group (median of 5 vs. 7 days; p = 0.006).
Conclusion:
There was no significant evidence of increased bleeding or need for blood transfusion during CABG in patients pretreated with clopidogrel. The current practice of clopidogrel pretreatment before percutaneous coronary intervention does not significantly increase the risk of hemorrhagic complications in stable patients provided they can wait for at least 7 days before CABG. In a single center retrospective study, clopidogrel pretreatment was not found to be associated with increased bleeding or need for blood transfusion during coronary artery bypass graft surgery, suggesting that clopidogrel pretreatment before percutaneous coronary intervention does not significantly increase the risk of hemorrhagic complication in stable patients provided they can wait for 7 days before the surgery.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Venous Thrombosis IV: Nursing Management